Study Protocol  
CTN-0093: Validation of a Community Pharmacy -Based Pres cription Drug Monitoring Program 
Risk Screening Tool  
NCT039369  
Document Date: May 25, 2021  
 
 
 
 
 
 
NIDA CTN Protocol 00 93 
 
VALIDATION OF A 
COMMUNITY  PHARMACY -BASED 
PRESCRIPTION DRUG MONITORING 
PROGRAM RISK SCREEN ING TOOL 
(PHARMSCREEN)  
 
 
 
Lead Investigator  (LI): Gerald Cochran, PhD   
 
Co-LI: Theresa Winhusen, PhD  
  
 
Funded by : National Institute on Drug Abuse (NIDA)  
May 25, 2021 
Version 2.0

 NIDA CTN -0093 Version 2.0 
 PharmScreen  May. 25, 21  
 
i  
 
Lead Investigator (LI):      Gerald Cochran, PhD  
     Greater Intermountain Node 
    University of Utah  
 
Co-LI:     Theresa Winhusen, PhD   
     Ohio Valley Node 
    University of Cincinnati  
 
Co-Investigator     Jennifer Brown, PhD  
    Ohio Valley Node 
    University of Cincinnati  
 Co-Investigator     Margie Snyder, PharmD , MPH, FCCP  
    Ohio Valley Node 
    Purdue University   
 
Project Manager     Irene Ewing    
    Ohio Valley Node 
    University of Cincinnati  
 CCTN Scientific Officer :     Udi Ghitza, PhD  
    National Institute on Drug Abuse  
  
 NIDA CTN -0093 Version 2.0 
 PharmScreen  May. 25, 21  
 
2 
 TABLE OF CONTENTS  
 LIST OF ABBREVIATION S ............................................................................................  5 
 STUDY SYNOPSIS ................................................................................................ ......... 6  
 S TUDY OBJECTIVES  ................................................................................................ ....... 6  
 S TUDY DESIGN  ................................................................................................ .............. 6  
 S TUDY POPULATION  ................................................................................................ ...... 6  
 A SSESSMENTS  ................................................................................................ .............. 6  
 A NALYSES  ................................................................................................ ..................... 7  
 STUDY SCHEMA  ................................................................................................ ............ 8  
 BACKGROUND AND RATIO NALE  ................................................................ ................ 9  
 B ACKGROUND  ................................................................................................ ............... 9  
 R ATIONALE ...................................................................................................................10  
 S IGNIFICANCE TO THE FIELD ..........................................................................................10  
 OBJECTIVES .................................................................................................................11  
 P RIMARY OBJECTIVE  ....................................................................................................11  
 S ECONDARY OBJECTIVE  ................................................................................................11  
 STUDY DESIGN  ............................................................................................................12  
 O VERVIEW OF STUDY DESIGN  .......................................................................................12  
 D URATION OF STUDY AND VISIT SCHEDULE  ....................................................................12  
 R ECRUITMENT SITES AND PARTICIPANT SELECTION ........................................................12  
 Site Selection ..........................................................................................................12  
 Participant Selection ................................................................................................13  
 STUDY ASSESSMENTS ...............................................................................................14  
 O VERVIEW OF ASSESSMENTS  ........................................................................................14  
 P RIMARY MEASURES OF INTEREST  ................................................................................14  
 NS metric  ................................................................................................................14  
 WHO ASSIST  ..........................................................................................................14  
 TAPS Tool  ...............................................................................................................15  
 O THER STUDY MEASURES  ............................................................................................ 15 
 Prescription Opioid Misuse Index  ............................................................................15  
 Overdose Experiences, Self and Witnessed—Drug  .................................................15  
 Brief Pain Inventory  ................................................................................................. 15 
 Short Form -12 .........................................................................................................15  
 Patient Health Questionnaire ...................................................................................15  
 S AFETY MEASURES  ......................................................................................................16  
 O THER MEASURES  .......................................................................................................16  
 Recruitment/Screening Assessments  ......................................................................16  
 Self-screening assessment ......................................................................................16  
 Additional PDMP Data .............................................................................................16  
 NIDA CTN -0093 Version 2.0 
 PharmScreen  May. 25, 21  
 
3 
 
 STUDY PROCEDURES  ................................................................................................. 17 
 O VERVIEW OF PROCEDURES  .........................................................................................17  
 P ARTICIPANT RECRUITMENT AND CONSENT  ................................................................... 17 
 S CREENING  ..................................................................................................................18  
 P REMATURE WITHDRAWAL OF PARTICIPANTS  ................................................................. 18 
 S TUDY HALTING RULES  ................................................................................................18  
 F OLLOW -UP .................................................................................................................18  
 P ARTICIPANT REIMBURSEMENT  .....................................................................................18  
 STATISTICAL DESIGN A ND ANALYSES  ..................................................................... 19 
 G ENERAL DESIGN  .........................................................................................................19  
 Study Hypotheses  ...................................................................................................19  
 R ATIONALE FOR SAMPLE SIZE AND STATISTICAL POWER  .................................................19  
 Projected Number of Sites  .......................................................................................19  
 Projected Number of Participants per Site  ...............................................................19  
 S TATISTICAL METHODS FOR PRIMARY AND SECONDARY OUTCOMES  ...............................20  
 S IGNIFICANCE TESTING  ................................................................................................. 20 
 M ISSING DATA AND DROPOUTS  .....................................................................................20  
 D EMOGRAPHIC AND BASELINE CHARACTERISTICS  ..........................................................20  
 REGULATORY COMPLIANCE, REPORTING AND MON ITORING  ..............................21  
 R EGULATORY COMPLIANCE  ...........................................................................................21  
 S TATEMENT OF COMPLIANCE  ........................................................................................21  
 INFORMED CONSENT  ....................................................................................................21  
 Q UALITY ASSURANCE MONITORING  ...............................................................................22  
 P ARTICIPANT AND DATA CONFIDENTIALITY  .....................................................................22  
 FINANCIAL DISCLOSURE /CONFLICT OF INTEREST  ............................................................23  
 P ERFORMANCE MONITORING  ........................................................................................23  
 INCLUSION OF WOMEN AND MINORITIES  .........................................................................23  
 P RISONER CERTIFICATION  ............................................................................................ 24 
 R EGULATORY FILES ..................................................................................................24  
 R ECORDS RETENTION AND REQUIREMENTS  ................................................................24  
 R EPORTING TO SPONSOR  ..........................................................................................24  
 A UDITS  .....................................................................................................................24  
 S TUDY DOCUMENTATION  ...........................................................................................24  
 P ROTOCOL DEVIATIONS  ............................................................................................ 25 
 S AFETY MONITORING  ................................................................................................25  
 Data and Safety Monitoring Board (DSMB)  ..........................................................25  
 T RAINING  ..................................................................................................................25  
 DATA MANAGEMENT  ..................................................................................................26  
 D ESIGN AND DEVELOPMENT  ..........................................................................................26  
 S ITE RESPONSIBILITIES  ................................................................................................. 26 
 D ATA CENTER RESPONSIBILITIES  ..................................................................................26  
 D ATA COLLECTION  .......................................................................................................26  
 NIDA CTN -0093 Version 2.0 
 PharmScreen  May. 25, 21  
 
4 
 
 D ATA MERGE  ...............................................................................................................26  
 D ATA ACQUISITION AND ENTRY  .....................................................................................27  
 D ATA TRANSFER /LOCK ................................................................................................. 27 
 D ATA TRAINING  ............................................................................................................27  
 D ATA QUALITY ASSURANCE  ..........................................................................................27  
 PUBLICATIONS AND OTHER RIGHTS  ........................................................................28  
 PROTOCOL SIGNATURE P AGE  ..................................................................................29  
 REFERENCES  ...............................................................................................................30  
 APPENDIX: DATA AND S AFETY MONITORING PLA N ...............................................34  
 
  
 NIDA CTN -0093 Version 2.0 
 PharmScreen  May. 25, 21  
 
5 
 
 LIST OF ABBREVIATIONS  
 
Abbreviation  Full Name  
AUC  Area under the curve  
BPI Brief Pain Inventory  
CTN Clinical Trials Network  
LI Lead Investigator  
NS Metric  Narcotic Score Metric  
OVN  Ohio Valley Node  
OUD  Opioid use disorder  
OESW -D Overdose Experiences, Self and Witnessed -Drug  
PHQ -2 Patient Health Questionnaire -2 
PDMP  Prescription Drug Monitoring Program  
POMI  Prescription Opioid Misuse Index  
POUD  Prescription opioid use disorder  
ROC  Receiver operating characteristic  
SF-12 Short Form -12 
TAPS  Tobacco, Alcohol, Prescription medication and other  Substances  
WHO ASSIST  World Health Organization Alcohol, Smoking, and Substance Involvement 
Screening Test 
 
 NIDA CTN -0093 Version 2.0 
 PharmScreen  May. 25, 21  
 
6 
 
 STUDY SYNOPSIS  
 Study Objectives  
Using opioid therapy to treat pain effectively, while minimizing potential adverse consequences, 
is an important goal. Appriss Health has developed the “Narcotic Score,” referred to as the “NS 
metric” hereafter, which uses Prescription Drug Monitoring Program (PDMP) data on opioid and 
sedative prescriptions and aberrant drug behavior (e.g., multiple providers, pharmacies, etc.) to 
compute a score quantifying the extent of the patient’s risk fo r opioid- related adverse events  in 
relation to all prescription opioid users. The association between the NS metric and other 
indicators of opioid use or risk has not been evaluated, and hence, the degree to which this metric 
is a useful  clinical screening tool is unknown. In addition to the NS metric, the Tobacco, Alcohol, 
Prescription medication and other Substances (TAPS) tool is rapidly becoming recognized as a high-quality substance use screening measure  for outpatient health care settings. Given the 
somewhat limited opioid- using sample in the TAPS tool validation study (≤5% for prescription 
opioids; <4% for heroin
1), the current study provides the opportunity to (1) to better assess the 
validity of the TAPS Tool as it would be used in clinical practice in community pharmacy  settings  
(including rural locations), and (2) to provide more clinically useful information for the use of the 
TAPS To ol by community pharmacists . The present study has two objectives : 
1) Evaluate the concurrent validity of the NS metric as a clinical measure of high risk opioid 
use and establish clinically useful risk -level thresholds relative to the widely validated gold 
standard of the World Health Organization Alcohol, Smoking, and Substance Involvement 
Screening Test (WHO ASSIST).2  
 
2) Collect TAPS tool data in a large sample of individuals filling opioid pain medications  to 
facilitate  further validation of this instrument with the WHO ASSIST.  
 Study Design  
This study is a one group, cross -sectional, health assessment study . Participants who enroll in 
the study will complete on-line surveys  of opioid utilization and risk, overdose history, substance 
use, mental health, and physical health at a single time point. Appriss Health will provide NS 
metric scores for all participants. These data will also be used to 1) validate and to identify clinical 
cut-off values for the NS metric  and 2) to further validate the TAPS tool .  
 Study Population  
Approximately 1,523 patients will be recruited from approximately 15 community Kroger 
community pharmacies. Trained pharmacy staff will inform potentially eligible participants , or 
individuals receiving  at least one  prescription(s) for potentially eligible participants , of the survey 
opportunity. Interested patients will complete  an encrypted electronic “interest survey ,” which  will 
trigger REDCap to email the patient a link to a secure web- portal contai ning e-consent (i.e., an 
electronic information sheet that is submitted by participants indicating their consent to participate in the study) and self -screening assessment forms. Following submission of the e -consent and 
successful qualification on the sel f-screening assessment , the health survey  will be  made 
available to participants for completion . The REDCap audio features will be enabled to allow 
participants with any reading difficult to request specific items be read out lou d.   
 Assessment s 
The key as sessments are: 1) The NS metric , obtained from Appriss  Health , which is a continuous 
indicator on a 000- 999 scale (higher scores indicate increased risk for adverse opioid- related 
 NIDA CTN -0093 Version 2.0 
 PharmScreen  May. 25, 21  
 
7 
 outcomes) ;3,4   2) The WHO ASSIST ; and (3) the TAPS Tool. The WHO ASSIST and TAPS Tool  
will be completed by participants through a secure REDCap- hosted web portal. Other 
assessments to be captured via self -report through the  secure REDCap -hosted web portal 
include:  1) opioid medication misuse assessed with  the Prescription Opioid Misuse Index (POMI) ;5 
2) pain severity assessed by  the Brief Pain Inventory  (BPI) ;6 3) general health status measured 
with a 1-item subscale from the Short Form (SF)-12;7 4) depression assesse d with the Patient 
Health Questionnaire (PHQ) -2;8 and 5) overdose frequency history assessed using the Overdose 
Experiences, Self and Witnessed (OESW -D)—Drug instrument .9  
 Analyses 
A series of a priori  analyses will be conducted to evaluate the validity of the NS metric relative to 
the widely validated gold standard WHO ASSIST and  to identify cutoff thresholds . A priori 
analyses will involve conducting Receiver Operating Curve Analyses ( ROC; i.e., sensitivity and 
specificity, area under the curve [AUC]) to identify clinical cutoff values for the NS metric and low, 
moderate, and high WHO ASSIST scores.  We will also conduct correlational, regression, and 
Cohen’s Kappa statistical analyses to evaluate the relationship between the NS metric and the 
WHO ASSIST .   
 
We will also conduct exploratory  correlational and regres sion, and Cohen’s Kappa statistical 
analyses to validate the relationship between the NS metric and measure s of opioid medication 
misuse as well as history of opioid overdose. Exploratory ROC, c orrelational, regression, and 
Cohen’s Kappa statistical analyses between the WHO ASSIST and the TAPS Tool will also be 
conducted.  
 NIDA CTN -0093 Version 2.0 
 PharmScreen  May. 25, 21  
 
8 
 
 STUDY SCHEMA   
 
 
• Adult patients at participating Kroger Pharmacies in Ohio and Indiana 
will be approached while picking up qualifying opioid medications  
• Pharmacy staff  shares details of study  
• Persons picking up medications for others will receive a study flyer with 
instructions on how the opioid recipient  may remotely complete the 
interest form 
 
▼ 
 
• Patient inputs contact information into REDCap interest form 
• Patient receives  email  link to e -consent and self -screening assessment  
 
▼ 
 
• Upon successfully qualifying on the  self-screening assessment  and 
completing the e -consent , the health assessment survey is made 
available to the participant  
 
▼ 
 
• Participant  completes survey, which includes : 
 
1. WHO ASSIST  
2. POMI  
3. TAPS Tool  
4. OESW -D  
5. PHQ -2 
6. SF-12 (general health subscale)  
7. BPI 
8. Demographics  
 
▼ 
 
• Ohio Valley Node ( OVN ) staff verifies the participant has not previously 
completed the survey and, if verified, sends participant $50  
 
▼ 
 
• Data are  checked for completeness , stored in HIPAA compliant 
environment, and merged regularly with NS metric  
• Final merged dataset with NS scores and health assessments are 
shared with OVN and University of Utah  
• Data are analyzed and results are reported  
 
 
 NIDA CTN -0093 Version 2.0 
 PharmScreen  May. 25, 21  
 
9 
 
 BACKGROUND AND RATIONALE  
 Background  
The US opioid epidemic continues to have serious public health ramifications. In 2017, nearly 
11.1 million individuals in the US reported misuse of opioid pain- relievers in the past year,10 with 
approximately 36% obtaining opioid medications for misuse through filling medications from a 
prescriber.10 A robust literature in the last decade has documented a clear trajectory for individuals 
who begin with opioid medication misuse transitioning to heroin use.11-22 In 2017, over 650,000 
individuals in the US reported past -year heroin use.10 Fatal overdose deaths involving prescription 
opioids , heroin, and synthetic opioids  has continued to increase across the US —continuing to 
increase in 35 states from 2013 -2017.23 Given these persistent trends for adverse opioid- related 
outcomes in populations across the US, it is critical to work to  identify those who are at risk, deliver  
appropriate care that will help prevent progression to more severe opioid- related outcomes , and 
provide referral and treatment resources  to those who suffer from opioid use disorder ( OUD ). 
Therefore, it is necessary to expand the continuum of care to health care settings that previously 
may have been underutilized.   
One underutilized resource for addressing the current opioid epidemic is community pharmacies. In the US, 93% of individuals live within 5 miles
24 of the >60,000 community pharmacies that 
employ >170,000 pharmacists.25 National data show that >40% of community pharmacies have 
private counseling rooms where pharmacists can discretely and confidentially provide care.26 
Pharmacists are ranked among the top 2 most trusted professionals in the US,27 with research 
showing patients are willing to receive behavioral health information from these professionals.28  
Previous research among pharmacists has further provided support for possible identification and intervention by community pharmacists for opioid misuse among patients.  Results of a survey in 
2 states (N=739) about opioid medication misuse and possible screening and intervening found 
that most pharmacists (90%) wanted to help patients who misuse opioid pain medications but 
reported needing training (81%) and tools (80%) to effectively do so.
29,30  Furthermore, results 
from 333 patients (response=71.2%) screened in 4 community pharmacies receiving  opioid 
medications found opioid medication misuse among 15% of patients.31 Among those with misuse, 
98% had ≥1 comorbid health condition known to increase risk for misuse or overdose, including 
depression, posttraumatic stress, risky alcohol use, and poor health and pain exceeding US 
norms. Patients  in this sample were agreeable to pharmacists screening their opioid medication 
use (70.9%) and discussing medication use if pharmacists had a concern (82.1%; with no 
differences between misusing and non -misusing respondents, p>.05).32,33 Given this important 
foundation for the expansion of the role of community pharmacy to address the opioid epidemic, 
it is critical to identify opportunities to better equip these health care professionals with tools to 
identi fy patients who are at risk for opioid- related adverse events.   
The most important clinical tool pharmacists have available to identify possible misuse of opioid 
medications is prescription drug monitoring programs (PDMP),34-41 which capture patient -level 
prescription dispensing information to inform monitoring, dispensing decisions, and possible 
intervention.35,36,38,41 These tools are available in all US states  (Missouri relies on a county -
administered program)  and have the potential to enable pharmacists to identify patients at -risk for 
opioid- related adverse events, such as addiction and overdose. Appriss Health is the largest 
PDMP platform vendor in the US, providing PDMP services statewide in 42 states, with approximately 1 million users. The Appriss platform facilitates PDMP data sharing in 44 states and captures 8 million monthly transactions. PDMP programs, such as the Appriss platform, have 
demonstrated clear results for reducing opioid prescribing.
35-41 PDMP effectiveness has not been 
clear on substance use outcomes,38 including rates of overdose.42-44 PDMP output data are limited 
 NIDA CTN -0093 Version 2.0 
 PharmScreen  May. 25, 21  
 
10 
 in clinical utility, do not provide decision support, and thus users must act  on “best judgment” to 
provide patient care and referrals with a limited evidence base.  Appriss Health has developed an 
opioid risk measure, the NS metric, which could support community pharmacists’ decision- making 
regarding interventions for  opioid risk. However, the validity of the NS metric has not been 
evaluated.  
 Rationale  
In light of the continued escalation of  the opioid epidemic nationally , combined with the promising 
opportunities afforded by the further inclusion of community pharmacy settings for engaging 
patients with opioid- related risk, it is important to evaluate whether  current PDMP risk metrics  
correlate with clinically validated opioid risk tools  and if clinically meaningful risk cutoffs exist for 
PDMP risk metrics . The present  study will accomplish two important objectives.  
 
First, the NS metric  has not been empirically validated with standardized opioid risk tools. This 
formative research projec t will leverage  public/private part nerships among the OVN , University of 
Cincinnati, University of Utah, Purdue University,  Appriss Health, and Kroger Pharmacies to 
validate and identify risk thresholds for the NS metrics through comparison with the widely 
validated gold standard WHO ASSIST. Successfully completing this objective is the first important 
step in understanding the validity of current PDMP metrics  and establishing clinically meaningful 
risk tools for opioids, which would allow community pharmacists to accurately and rapidly triage 
patient opioid risk. These results will provide foundational data that will allow our team to continue 
this line of research and further collaborate with Appriss Health to identify  and test a PDMP -based, 
opioid-f ocused,  decision support tool for community pharmacies.   
 
The second  objective of this study is  to further validate the TAPS tool. Mentioned previously , the 
TAPS tool is rapidly becoming recognized as a high- quality  substance use screening measure for 
outpatient health care settings.  1  The recent validation study for this tool, conducted  with primary 
care patients , showed high levels of sensitivity and specificity for tobacco and heavy alcohol use 
(>0.79), and adequate sensitivity and specificity for illicit and prescription drug use ( >0.63).1 Given 
the somewhat limited opioid using sample in the validation study (≤5% for prescription opioids; 
<4% for heroin1), the current study provides the opportunity (1) to better assess the validity of the 
TAPS Tool as it would be used in clinical practice in community pharmacy settings  (including rural 
locations) , and (2) to provide more clinically useful information for the use of TAPS Tool by 
community pharmacists . 
 Significance to the Field  
 
The first study objective builds on previous research from our team that has focused on 
understanding the needs and opportunities available for identification of , and intervention for, 
problematic opioid use among  community pharmacy patients prescribed opioid 
medications.29,30,45- 47 The results of this project stand to meet several important needs of 
community pharmacy to increase their involvement in the identification of patients at -risk for 
opioid- related adverse events, such as addiction and overdose. Specifically, if the first objective 
is achieved, the results from this study would enable rapid identification of opioid- related risk 
utilizing data from a widely -available PDMP platform vendor (Appriss Health).  
 
The second study objective also builds on previous research from CTN investigators1,48 and 
stands to extend the knowledge base  in the field r egarding the utility of the TAPS Tool as a 
universal substance use screening instrument for outpatient clinical care settings . 
 NIDA CTN -0093 Version 2.0 
 PharmScreen  May. 25, 21  
 
11 
 
  OBJECTIVES  
 Primary Objective  
The primary objective of this project is to validate and identify low, moderate, and high risk 
thresholds for the NS metric through comparison to the widely validated gold-standard WHO 
ASSIST measure for opioid use risk in adult community pharmacy patients dispensed opioid 
medication therapies .  
 Secondary objective  
The secondary objective of this  study  is to collect  data to further validate the TAPS Tool. This 
measure will be compared to the WHO ASSIST in a novel sample of adult out patients from 
community pharmacies  with active opioid medication prescriptions.  
 NIDA CTN -0093 Version 2.0 
 PharmScreen  May. 25, 21  
 
12 
 
 STUDY DESIGN   
 Overview of Study Design   
We will implement a one -time, cross -sectional, self -administered, health survey  among eligible 
adult patients dispensed  opioid medications from 15 participating Kroger pharmacies in Ohio  and 
Indiana. This design will accomplish the purpose of the study given that it will allow for recruitment 
of a sample of patients with sufficient power to identify and validate clinical threshold values for 
the NS Metric . Patients recruited will complete a series of  validated  measures to assess  opioid 
use and risk behaviors , substance use, and physical and mental health.  
Study survey data will be merged  on a regular basis  with the NS metric by Appriss Health and 
shared with OVN and University of Utah investigators f or assessment of data quality and to 
conduct  statistical analyses. See section 11.9 for an overview of Data Quality Assurance. Appriss 
Health will deterministically match and merge the survey data with the NS metric  using patient 
contact information ( e.g., name, address, phone number) as well as information regarding the 
location of the pharmacy and time/dates for when the study interest form was completed and 
submitted into REDCap .  
 Duration of Study and Visit Schedule  
Enrollment is expected to take place over a period of approximately 6-8 months. Enrolled 
participants will complete surveys at a single time point, which will take appr oximately 35- 40 
minutes to complete.  
 Recruitment Sites and Participant Selection  
  Site Selection  
Participating University sites for this project include, the: University of Cincinnati, University of 
Utah, and Purdue University. Recruitment sites for the study include approximately 12 Kroger 
Pharmacies in Ohio and approximately 3 rural Kroger Pharmacies in Indiana. The rural Indiana 
pharmacy locations will be identified as rural by meeting at least one of the definitions of rural 
using the “Am I Rural” online tool ( https://www.ruralhealthinfo.org/am -i-rural).  
6.3.1.1  Recruitment Site Characteristics  
Study site characteristics reflect  the need to recruit community pharmacy patients receiving opioid 
medications in urban and rural settings  in order  increase the generalizability of the study results. 
For study feasibility, it was determined that each recruitment site also needed to be a Kroger 
pharmacy in the state of Ohio or rural Indiana that filled an adequate number of patients’ opioid 
prescriptions. The Kroger Pharmacy chain was selected as the partner for this project based on 
4 primary reasons:  
 
1. Sites selected will dispense and average of  ≥300 patients’ opioid prescriptions within a 
6-month period, resulting in a patient pool of approximately  ≥4,500 potential participants; 
 
2. Kroger and Appriss  Health  have a long history of collaboration, and therefore partnering 
on this project will be familiar to both companies. Kroger also has a long history of 
collaboration with University of Cincinnati and Purdue University.   
3. Kroger is the 5th largest pharmacy chain in the US, and thus represents a possible scalable service setting if the primary objective of the current study is successful.  
 
 NIDA CTN -0093 Version 2.0 
 PharmScreen  May. 25, 21  
 
13 
 4. Kroger corporate offices are located in Cincinnati, Ohio . Thus, working with company 
leadership and staff training will be facilitated by proximity to the OVN investigative 
teams at the University of Cincinnati and Purdue University Indianapolis campus es.  
 In addition to the above points, the study investigative team  will work closely with Kroger 
Pharmacy to select pharmacy locations within ethnically and racially diverse populations to 
promote the recruitment of a diverse study sample.   
  Participant Selection  
This study will enroll  approximately 1,523 patients who w ill complete a web -based health survey .  
 
6.3.2.1  Inclusion Criteria  
Potential participants must : 
1. be dispensed ≥1 opioid medication (including tramadol ) by a participating Kroger 
Pharmacy ; 
 
2. be ≥18 years of age according to Kroger Pharmacy  data and self -report  
 
6.3.2.2  Exclusion Criteria  
Potential participants must not self -report : 
1. solely filling buprenorphine or buprenorphine combination products i.e., patients receiving OUD treatment with no other opioid medication use; 
 
2. currently receiving treatment for cancer ; 
 
3. having  previously completed the survey ( this will be re -verified by OVN staff by 
examining identifying information following health assessment submission);  
 
4. having current involvement with the criminal justice system that has, or could, lead to 
incarceration  
Mentioned above, we will enable REDCap audio features to allow participants with any reading difficult to request specific items be read out loud.   
 NIDA CTN -0093 Version 2.0 
 PharmScreen  May. 25, 21  
 
14 
 
  STUDY ASSESSMENTS  
 Overview of Assessments 
The selection of assessments  was based  on the validity of the assessments,  costs  of data 
collection in terms  of participant t ime and staff time and training,  and feasibility of 
comp letion.    
 Primary Measures of Interest  
Unlike a clinical trial evaluating the impact o f an intervention, the present study  is a validation 
study , and thus, does not include traditional outcome measures.  
  NS metric  
The NS metric  is a continuous indicator on a 000 -999 scale, with the last digit representing 
number of active opioid prescriptions (those with ≥9 prescriptions coded as 9) and the first two 
numbers representing a composite risk score. Higher scores indicate increased risk for adverse 
opioid- related outcomes (e.g., overdose). The first two digits of the score are based on 
deterministic calculations3,4 and use well -known indicators associated with opioid- related 
adverse events.49-52 These calculations are produced through t he following steps:  
1) For a given patient, raw indicators of five risk factors are extracted from PDMP data: (a) 
morphine milligram equivalents (MME) dispensed, (b) lorazepam milligram equivalents 
(LME) dispensed, (c) overlapping prescription days, (d) number of prescribers, and (e) numbers of pharmacies.  
2) Each raw indicator is converted to a scaled value between 0 and 99 (based on percentiles 
from a large PDMP reference population), for four time periods: (a) past 2 months, (b) past 6 months, (c) past 12 months, and (d) past 24 months. Therefore, each patient is assigned 
20 scaled percentile values. These scaled values weigh the contribution of recent values 
more heavily than values further in the past; for example, having 6 unique prescribers over 
the past 2 months has a greater scaled percentile score (i.e., 85) than having 6 unique 
prescribers over the past 2 years (i.e., 30).  
3) Scaled values for each of the five indicators are averaged across their four respective time 
periods.  
4) A weighted sum of the five averaged values is calculated: MME is given a weight of 3; 
overlapping medication days is given a weight of 2; and LME, number of prescribers, 
number of pharmacies are each given a weight of 1. This sum is divided by 8 to produce a 
weighted average, yielding a two- digit composite risk score; these are the first two digits of 
the NS metric.  
5) The total number of active opioid prescriptions is appended to the two- digit composite risk 
score, to form the final three- digit NS metric.  
  WHO ASSIST  
The WHO ASSIST  will be used as the gold standard to which the NS metric will be  compared. 
The WHO ASSIST  was constructed in a large -scale multi- country study, which demonstrated 
criterion, construct, concurrent, discriminant validity.2 This assessment contains between 8- 74 
Likert scale items, depending on the number of substances endorsed by study participants, and 
will require 5 -15 minutes to complete. The WHO ASSIST asks about use of the following 
 NIDA CTN -0093 Version 2.0 
 PharmScreen  May. 25, 21  
 
15 
 substances in the past 3 months and lifetime: tobacco, alcohol, cannabis, cocaine, 
amphetamine, inhalants, sedatives, hallucinogens, opioids, and other drugs.  
In addition to the WHO ASSIST, we will capture 2 additional opioid items from an adapted WHO 
ASSIST, developed by McNeely, et al.53 In this  adapted version, opioid items specifically inquire 
about use of prescription opioids and heroin. These items have been tested in an audio assisted 
computerized format and have demonstrated reliability.53 These items will not be used in our a 
priori assessment of the NS score and the WHO ASSIST.  
  TAPS  Tool 
Substance use will also be captured using TAPS 1/2 tool , which has demonstrated concurrent 
validity. 1 This assessment contains between 5- 14 items regarding a respondent’s substance 
use in the last 3 and 12 months. It specifically addresses use of tobacco and alcohol as well as 
illicit and prescription drug misuse. This assessment will require 5 -15 minutes to complete. This 
measure will be captured to provide additional information regarding its psychometric properties 
compared to the WHO ASSIST.  
 Other  Study Measures  
Additional measures of opioid misuse, overdose, health, and mental health will also be collected 
in order to describe the participant population, adjust analytical models, and perform exploratory 
analyses .  
  Prescription Opioid Misuse Index  
Opioid medication misuse will be captured using the Prescription Opioid Misuse Index, which 
has demonstrated criterion validity.5 This measure contains 6 yes/no items about an individual’s 
current use of opioid medications and covers domains such as early refills, taking more than prescribed, doctor shopping, and using the medication to cope with problems. This assessment will require 5 minutes or less to compete.  
  Overdose E xperiences, Self and Witnessed —Drug  
Overdose frequency history will be assessed using the overdose frequency item from the  
criterion -valid Overdose Experiences, Self and Witnessed—Drug instrument.9 This single item 
asks respondents how many times in their lifetime they have experienced a drug overdose. This assessment will require 1 minute or less to compete.  
  Brief Pain Inventory  
Pain severity will be assessed using the Brief Pain Inventory (BPI ), a well -validated, reliable 
instrument that consists of a 4 -item pain Intensity subscale and a 7 -item pain interference 
subscale.6 This BPI will require 5 minutes or less to compete.  
  Short Form -12 
General health status will be measured using a 1-i tem subscale from the construct -valid Short 
Form -12.7 This Likert scale item asks respondents to rate their general health from excellent to 
poor. This assessment will require 1 minute or less to compete.  
  Patient Health Questionnaire 
Depression will be captured using the criterion- valid  Patient Health Questionnaire- 2.8 This 2 -
item assessment asks respondents to rate on a Likert scale (ranging from ‘n ot at all’ to ‘nearly 
 NIDA CTN -0093 Version 2.0 
 PharmScreen  May. 25, 21  
 
16 
 every day’ ) their interest or pleasure in doing things and feeling of being down or depressed  in 
the last two weeks. This assessment will require 1 minute or less to compete.  
 Safety Measures  
This study  will not involve  the use of any clinical interventi on or medi cations.  The only expected  
risk to participants  is a loss of confident iality, which wi ll be minimized by  utilizing an encrypted 
REDCap platform.  Any breach of confidentiality  will be reported on a protocol  deviation  form. 
Data security will also be ensured for transferring data files to and from Appriss Health by 
utilizing a HIPAA compliant, encrypted, and secure data storage cloud site.   
 Other Measures  
  Recruitment/ Screening Assessments  
Recruitment  – Kroger Pharmacy staff will aid in track ing which patients have been provided with 
information about the study  and how that information was shared.    
 
Interest form  – Participants interested in learning more about the study will complete an electronic 
“interest form” in which they provide their contact information as well as basic demographic 
characteristics (e.g., age, sex, race/ethnicity). Kroger pharmacy staff will be available to answer 
participant questions regarding the interest form. If completing the interest form remotely, study 
staff’s contact information will be available for potential participants to call for assistance.  
 
  Self-screening assessment  
Following e -consent, participants will complete a self -screening assessment , which will include 
questions about opioid medication prescriptions (including Kroger Pharmacy at which the 
qualifying prescription was filled), whether they are being treated for cancer, have involvement with the criminal justice system, and whether they have participated in the study previously. 
Study staff’s contact information will be shared on the e- consent form , self-screening 
assessment, and the health survey. They will be available to answer any questions the 
participant may have.  
  Additional  PDMP Data  
Appriss Health may also provide, in addition to the NS metric, other related data that possibly 
will be informative for the objectives of this study. Examples of these other data elements could 
include non- opioid medication information, prescribing information, and/or di spensing 
information.  
 
 NIDA CTN -0093 Version 2.0 
 PharmScreen  May. 25, 21  
 
17 
 
 STUDY PROCEDURES   
 Overview of Procedures  
Table 1 provides an overview of the participant procedures and assessments.  
 
Table 1. Overview of Assessments and Procedures 
Form  Done by  Before 
screening  Screening/ 
Eligibility  Assessment  
Recruitment Tracking  Pharmacy  x   
Interest form  Participant   x  
E-consent  Participant   x  
Self-screening  Participant   x  
 Assessment domain: Opioid Use  
Narcotic Score (NS metric)  Appriss    x 
WHO ASSIST: opioid items2 Participant    x 
Who ASSIST: adapted opioid Items53 Participant    x 
TAPS 1 / 2 Tool: Prescription drug and 
prescription opioid items1 Participant    x 
TAPS 1 / 2 Tool: Illicit drug and heroin 
items1 Participant    x 
Prescription Opioid Misuse Index5 Participant    x 
Overdose Experiences, Self and 
Witnessed—Drug  
(OESWD) 9 Participant    x 
 Assessment domain: Substance Use  
WHO ASSIST: Non-opioid drug use 
items2 Participant    x 
TAPS 1 / 2 Tool: Non-opioid items1 Participant    x 
 Assessment domain: Mental Health  
Patient Health Questionnaire -28 Participant    x 
 Assessment domain: Physical Health  
Short Form -12: General health 
subscale7 Participant    x 
Brief Pain Inventory6 Participant    x 
 Assessment domain: Demographics  
PhenX demographics: age, education, 
gender, race, ethnicity, insurance, 
employment, marital status  Participant    x 
 Participant  Recruitment and Consent   
A convenience sample of adult patients being dispensed opioid prescriptions  (including tramadol 
and not solely receiving buprenorphine or buprenorphine combination products) at any of the 
participating Kroger Pharmacy locations  will be recruited.  Recognizing the busy nature of the 
Kroger Pharmacy environment, we have intentionally  designed the recruitment process to require 
minimal pharmacy staff involvement, requiring staff to only assess the patients’ ages and 
prescription information to target potentially eligible participants.  Trained Kroger Pharmacy staff 
will inform potentially eligible participants of the survey opportunity. Interested patients will be 
handed a study flyer and an electronic device (e.g., tablet, etc.) with an electronic “interest survey.” 
Study flyers may also be given to customers picking up medications on behalf of others and those 
 NIDA CTN -0093 Version 2.0 
 PharmScreen  May. 25, 21  
 
18 
 who choose not to initially share contact information. The flyer will only be targeted to those who 
the pharmacy staff believes are eligible for the study. The flyer will direct  interested individuals to 
a secure web- version of the interest survey.  Interested patients will complete the encrypted 
electronic “interest survey,” which will trigger REDCap to email the patient a link to a secure web-
portal containing the e-consent (i.e., an electronic informed consent information sheet t hat is 
submitted by participants indicating their consent to participate in the study) .  
 
The IRB will be asked to waive the written informed consent  requirement  because this is a minimal 
risk study . This study, which includes participants completing on -line self -assessments, could not 
be practicably carried out if written consent were required. The IRB-approved e-consent  
information sheet  will include a description of all significant elements of the study: what 
participation entails; risks and benefits of study procedures; alternatives to participation in the study; confidentiality; $50 payment for participation information ; a statement that participation is 
voluntary and that the participant may withdraw at any time; and information about whom to 
contact with questions. The e- consent form will also indicate that the decision to participate will in 
no way influence other aspects of the participant’s  treatment , and participants’ data will not be 
shared with their clinicians .  
  
 Screening  
Following submission of the e -consent, the participant will complete  the screening self -
assessment , and  if qualified, the participant will be given access to the health survey.  
 Premature Withdrawal of Participants  
All participants  are allowed  to withdraw  consent at any stage  of the study.  In addition , 
the Ll, or designee,  can remove  the participant  from the study  when  there  is evidence  that 
the study  might  be harmful  to the participant.  
 Study Halting Rules  
Given that this study is low risk and does not provide a clinical  intervention of any type, it is not 
anticipated that study will be halted at any time. However, if for an unforeseen reason the study 
is prematurely terminated or temporarily suspended, the LI, or designee,  will promptly inform the  
respective IRB and sponsor and provide the reason(s) for the termination or temporary 
suspension. If the study is suspended, the investigative team will work with the appropriate parties to resolve the existing issue in order to reinitiate the study. 
 Follow -Up  
Participants who complete the e- consent  and are eligible for the study  but do not compl ete the 
health survey  within 3 business days will be contacted by study staff and encouraged to 
complete the survey.  
 Participan t Reimbursement   
Following submission of the completed survey and research staff verifying data are complete with valid answers (valid indicated by response patterns with no or minimal  missing values)  and are 
not a duplicate participant submission, partici pants will be provided with a $50 prepaid debit card. 
Partial compensation will not be provided to those who partially compl ete the survey. Mailing 
address information for participant compensation will be collected during the survey process.  
 
   
 
 NIDA CTN -0093 Version 2.0 
 PharmScreen  May. 25, 21  
 
19 
 
 STATISTICAL DESIGN AND ANALYSE S  
 General Design  
This study seeks  to evaluate the concurrent validity of the NS metric as a clinical measure of 
opioid risk and establish clinically useful risk -level thresholds relative to the WHO ASSIST. This 
study also seeks to collect data on the TAPS tool in a large sample of individuals filling opioid 
medications in order to further validate this instrument in a novel outpatient setting, community 
pharmacy . 
 Study Hypothes es  
Similar to the “ The TAPS Tool: Screen and Brief Assessment Tool Validation  Study , CTN-
0059”,  this study will not test any intervention or hypothesis .54 This study will focus on the level 
of agreement between the NS metric and participants' responses to opioid risk assessment 
questions. The goal of the project is to validate and identify risk cutoffs between the NS metric 
and the  WHO ASSIST. As such, the study is a measurement validation project and so has no 
primary outcome variables.54 See CTN 0093 Statistical Analysis Plan for details.  
 In addition to analyses involving the NS metric, we will examine the association of the TAPS 
Tool with the  WHO ASSIST risk categories. See CTN 0093 Statistical Analysis Plan f or details.  
 Rationale for Sample Size and Statistical Power   
  Projected Number of Sites   
This study will involve 15 participating Kroger Pharmacies. Sites will include 12 Kroger 
Pharmacies in Ohio and 3 rural Kroger Pharmacies in Indiana.  
  Projected Numb er of Participants per Site  
Survey sample size power estimates are based on the allocation ratio of the national rate of prescription opioid use disorder (POUD) among those prescribed opioid medications in the last 
year (2.1%,
55 i.e. 46.6/1). Thus, the sample is powered to the least prevalent but most severe 
condition among potential patients . We calculated an array of sample sizes powered to achieve 
≥80% power (α=0.05) and 0.70 (“fair”) Area Under the Curve value, 56,57 using a conservative null 
hypothesis assumption of 0.5 for discrimination power (Table 2).58 Therefore, to ensure the 
maximum power for the study, we will target recruitment to 1,523 total patients.  
 
Table 2. Power Analyses (AUC=0.70, Discrimination Power=0.5)  
Power  N 
0.80 618 
0.85 714 
0.90 809 
0.95 1,047  
0.98 1,523  
 
Each Kroger pharmacy site will be responsible for approaching approximately 207 patients 
(~3,105 collectively). Of these, we anticipate 70% will be interested and agree to share their 
contact information.31 Of these, based on our current research among this population 
([STUDY_ID_REMOVED]), we anticipate 70% will actually provide e- consent and complete the survey. 
Therefore, each site will refer approximately 102 patients who will complete the e- consent and 
 NIDA CTN -0093 Version 2.0 
 PharmScreen  May. 25, 21  
 
20 
 survey. We will calculate the survey response rate based on the number of potential participants 
who submit contact information compared to the survey completion rate.  
 Statistical Methods for Primary and Secondary Outcomes  
A series of a priori analyses will be conducted to evaluate the validity of the NS metric relative to 
the widely validated gold standard WHO ASSIST and to identify cutoff thresholds. A priori 
analyses will involve conducting Receiver Operating Curve Analyses (ROC; i.e., sensitivity and 
specific ity, area under the curve [AUC]) to identify clinical cutoff values for the NS metric and 
low, moderate, and high WHO ASSIST scores. We will also conduct correlational, regression, and Cohen’s Kappa statistical analyses to evaluate the relationship between the NS metric and 
the WHO ASSIST.   
 We will also conduct exploratory correlational, regression, and Cohen’s Kappa statistical 
analyses to validate the relationship between the NS metric and measures of opioid medication 
misuse as well as history of opioid overdose. Exploratory ROC, correlational, regression, and Cohen’s Kappa statistical analyses between the WHO ASSIST and the TAPS Tool will also be 
conducted. Considerations in determining the statistical approach can be found in the CTN -
0093 Statistical Analysis Plan.  
 Significance Testing   
The analyses  will be conducted using a two- sided test with a type I error rate of 5%.  
 Missing Data and Dropouts   
This study  does  not include follow -up assessments,  and all study  assessments wi ll be 
completed  during  the electronic health assessment survey . Missing  data and dropouts  are 
expected to be relatively  minimal. Nonetheless,  the analysis  will determine the extent  of 
missing  data for all study  variables  and explore di fferences  in miss ing data by age, gender,  
and race/eth nicity. The completer population, defined as participants who complete opioid 
outcome score contributing items on the WHO ASSIST and TAPS tool, will be used for the 
main analysis. Completers also must have NS metric scores. Multiple imputation will be 
conducted for missing covariates , but missing key outcome data will not be imputed.  See CTN 
0093 Statistical Analysis Plan for details.  
 Demographic and Baseline Characteristics  
Baseline demographic and clinical variables will be summarized for enrolled participants. 
Descriptive summaries of the distribution of continuous baseline variables will be presented, 
with measures of central tendency. Categorical variables will be summarized in terms of 
frequencies and percentages.  In addition, analyses will be conducted on the primary and 
exploratory aims for male and female gender subgroups. See CTN-0093 Statistical Analysis 
Plan.  
 
  
 NIDA CTN -0093 Version 2.0 
 PharmScreen  May. 25, 21  
 
21 
 
 REGULATORY COMPLIANCE, REPORTING AND 
MONITORING  
 Regulatory Compliance   
This study will be conducted in full conformity with the ethical principles outlined in the 
Declaration of Helsinki, the Regulations for the Protection of Human Subjects codified in the 
International Council for Harmonization Good Clinical Practice (GCP) Guidelines, and all other 
applicable regulatory requirements. Written approval for the study protocol, e -consent form, 
other supporting documents, and any advertising for participant recruitment will be provided to 
the participating University sites and Kroger recruitment  sites by the Institutional Review Board 
(IRB) of record prior to participation in the study. Any amendments to the protocol or e- consent 
materials must be approved by the IRB of record before they are implemented. Unanticipated 
problems involving risk to study participants will be promptly reported to and reviewed by the 
IRB of record, according to its usual procedures. Annual progress reports will be submitted to 
the IRB, according to its usual procedures.  
 
This study will be registered and updated as needed in ClinicalTrials.gov . 
 State ment of Compliance   
This study will be conducted in accordance with the current version of the protocol, in full conformity with the ethical principles outlined in the Declaration of Helsinki, the Regulations for the Protection of Human Subjects codified i n the International Council for Harmonization Good 
Clinical Practice (GCP) Guidelines, and all other applicable regulatory requirements. Institutional Review Board Approval   
 Per NOT -OD-16-094, the University of Cincinnati IRB (UC IRB) will be the IRB of r ecord for the 
protocol and will provide study oversight in accordance with 45 CFR 46.  Participating institutions 
have agreed to rely the University of Cincinnati and have entered into reliance/authorization 
agreements for Protocol CTN 0093 . The University  of Cincinnati  will follow written procedures for 
reporting its findings and actions to appropriate officials at each participating institution , see Single 
Site IRB (sIRB) Plan .  
 Prior to initiating the study, university site investigators will obtain written IRB approval to conduct 
the study at their respective site, see sIRB Plan . If changes to the study protocol become 
necessary, protocol amendments will be submitted in writing by the investigators for IRB approval prior to implementation. In addition, IRBs will approve the e- consent form, recruitment materials, 
and any materials given to the participant, and any changes made to these documents throughout study implementation. For changes to the e- consent form, a decision will be made regarding 
whether previously enrolled participants need to be re- enrolled. IRB continuing review will be 
performed annually, or at a greater frequency contingent upon the complexity and risk of the study. Each site principal investigator is responsible for maintaining copies  of all current IRB 
approval notices, IRB -approved e- consent documents, and approval for all protocol modifications. 
These materials must be received by the investigator prior to the initiation of research activities at the site, and must be available at any time for audit.  
 Informed Consent   
The consent process is a means of providing study information to each prospective participant and provides an opportunity  for an informed decision about participation in the study.  Because 
this study is minimal risk, in volving  on-line completion of a survey at one time point, an altered 
 NIDA CTN -0093 Version 2.0 
 PharmScreen  May. 25, 21  
 
22 
 consent process will be utilized. Specifically, participants will access an IRB -approved electronic 
informed consent information sheet  (i.e., e -consent)  and indicate their consent to participate by 
selecting “continue” at the end of the sheet. The e-consent information sheet  must be updated or 
revised whenever important new safety information is available, or whenever the protocol is 
amended in a way that may affect participants’ participation in the study . The rights and welfare 
of the participants will be communicated  by emphasizing that the quality of their medical care or 
pharmacy services will not be adversely affected if they decline to participate in this study.  The 
participant will be informed that their participation is voluntary and they may withdraw from the 
study at any time, for any reason without penalty. Individuals who refuse to participate or who 
withdraw from the study will be treated without prejudice.  
 Quality Assurance M onitoring  
In accordance with federal regulations, the study sponsor is responsible for ensuring proper  
monitoring of an investigation and ensuring that the investigation is conducted in accordance with 
the protocol. Qualified local monitors will oversee participating University sites to ensure they are  
operating within the confines of the protocol  and in accordance with GCP.  Monitoring includes , 
but is not limited to , protocol compliance, documentation auditing, and reporting  safety  events . 
Non-conformity  with protocol and federal regulations can be reported as a protocol deviation and 
submitted to the study sponsor and study IRB for further review.  Reports will be prepared following 
monitoring reviews and forwarded to the investigative team and NIDA CCTN.  If the monitor’s  
review indicates that additional training of site study personnel is needed, QA personnel will undertake or arrange for that training. Monitoring will occur not more than quarterly  and not less 
than annually. Details of QA and data monitoring are found in the study QA Monitoring Plan.  
 Participant and Data Confidentiality   
Confidentiality will be maintained in accordance with all applicable federal regulations and/or 
state/Commonwealth law and regulations. By signing the protocol signature page , the investigator 
affirms that information furnished to the investigator by NIDA will be maintained in confidence and 
such information will be divulged to the IRB/Privacy Board, Ethical Review Committee, or similar 
expert committee; affiliated institution; and employees only under an appropriate understanding of confidentiality with such board or committee, affiliated institution, and employees.  
 
To further protect the privacy of study participants, the lead investigator will obtain a federal 
Certific ate of Confidentiality (CoC)  from NIH , which protects identifiable research inf ormation from 
forced disclosure  and will distribute it to all sites when received. This protect s participants against 
disclosure of sensitive information (e.g., drug use) . The C oC allows the investigator and others 
who have access to research records to permanently refuse to disclose identifying information on 
research participation in any civil, criminal, administrative, legislative, or other proceeding, 
whether at the federal, state, or local level, excepting certain circumstances . 
 
By protecting researchers  and institutions from being compelled to disclose information that would 
identify research participants, CoCs  help achieve the research objectives and promote 
participation in studies by helping assure confidentiality and privacy to participants.  The NIH office 
that issues the CoC will be advised of changes in the CoC application information. Participating 
sites will be notified if CoC revision is necessary. Participant records will be held confidential by 
the use of study codes for identifying participants on electronic case report forms  (eCRF), secure 
storage of any encrypted documents that have participant identifiers, and secure computing 
procedures for entering and transferring electronic data.  
 
 NIDA CTN -0093 Version 2.0 
 PharmScreen  May. 25, 21  
 
23 
 
 Financial Disclosure /Conflict of Interest  
All investigators will comply with the requirements of 42 CFR Part 50, Subpart F to ens ure that 
the design, conduct, and reporting of the research will not be biased by any conflicting financial 
interest. Everyone with decision- making responsibilities regarding the protocol will confirm to the 
sponsor annually that they have met their instit utional financial disclosure requirements. 
 Performance Monitoring 
OVN and University of Utah leadership  will develop a Performance Monitoring Plan. This plan 
will detail, according to the study timeline, progress the study will make to accomplish its goals . 
The plan will include the development  of performance metrics  and will likewise detail procedures 
and guidance for underperforming recruitment sites. Performance metrics will be assessed in 
regularly scheduled study meetings  (not to occur more than weekly  and less than monthly ). For 
these meeting s, a performance summary report will be made available to the research team. By 
pharmacy site, the report will include information such as:  
 Number of initiated vs. completed interest surveys  
 Number of completed interest surveys vs. expected by study timeline  
 Number of initiated vs. completed e- consent forms  
 Number of competed e- consent forms vs. expected by study timeline  
 Number of initiated vs. completed self -screening forms  
 Number completed self -screening forms v s. expected by study timeline  
 Description of reasons potential participants are screened as ineligible 
 Number of initiated vs. completed health assessment surveys  
 Number of completed health assessment surveys vs. expected by study timeline  
Based on the team’s regular comparison of these metrics by pharmacy recruitment site, low 
performing sites will be identified. Procedures for improvement of low performing sites will include actions such as:  
 Discussion of the site’s performance with Kroger  Corporate, Regional, and local 
management.  
 Performing on -site visit s to discuss performance issues, identify barriers, and make 
plans to increase performance.  
 Discussion and planning with research staff regarding outreach to participant s with 
initiated  and uncompleted forms .  
 Identification of possible additional Kroger pharmacy sites for outreach advertisement  
 Inclusion of Women and Minorities  
The study sites should aim and take steps to enroll a diverse study population. Noted in section 
2.3 of the study appendix, based on our previous research on this topic, we anticipate 57% of our 
sample will be female, and 43% will be male.  Assessments captured (i.e., TAPS Tool alcohol 
subscale) are specified for male vs. female respondents.  We also anticipate our study sample will 
approximate the racial/ethnic distributions of the local areas in which the recruitment stores 
operate. If difficulty is encountered in recruiting an adequate number of women and/or minorities, 
the difficulties involved in recruitment will  be discussed in national conference calls and/or face -
to-face meetings  and plans to correct these difficulties will be put into place .  
 
 
 
 NIDA CTN -0093 Version 2.0 
 PharmScreen  May. 25, 21  
 
24 
 
 Prisoner Certification  
As per 45 CFR 46 Subpart C, there are additional protections pertaining to prisoners as study  
participants. A prisoner is defined as any individual involuntarily confined or detained in a penal 
institution. The term is intended to encompass individuals sentenced to such an institution under 
a criminal or civil statute, individuals detained in other facilities by virtue of statutes or commitment 
procedures which provide alternatives to criminal prosecution or incarceration in a penal 
institution, and individuals detained pending arraignment, trial, or sentencing.  This study will not 
recruit individuals meeting this definition.  
 Regulatory Files   
Essential  documents  are those documents  which  individually  and collectively  permit  evaluation of 
the conduct  of a study  and the quality  of the data produced.  These  documents  serve  to demonstrate 
the compliance of the investigator, sponsor, and monitor with the standards of Good Clinical Practice and with all applicable regulatory requirements. The regulatory files should contain all 
required regulatory documents, study -specific documents, and all important communications. 
Regulatory files will be checked at each participating University site for regulatory document 
compliance prior to study initiation, throughout the study  according to regularly agreed upon 
schedule (not more than quarterly  and less than annually ), as well as at study closure by local 
research staff and quality monitors, see section 10. 4.  
 Records Retention and Requirements   
Research records for all study participants are to be maintained by the participating University 
site investigator in a secure location for a minimum of 3 years after the study is completed and 
closed. These records are also to be maintained in compliance with IRB, state and federal requirements, whichever is longest. The sponsor and Lead Investigator  must be notified in writing 
and acknowledgment must be received by the participating University site prior to the deletion or 
relocation of research records.  
 Reporting to Sponsor  
The investigative team  agrees to submit accurate, complete, legible and timely reports to the 
Sponsor, as instructed by the sponsor. These include, but are not limited to, reports of any 
changes that significantly affect the conduct or outcome of the study  or increase risk to s tudy 
participants. Safety reporting will occur as previously described. At the completion of the study , 
the Lead Investigator will provide a final report to the Sponsor.  
 Audits   
The Sponsor has an obligation to ensure that this study  is conducted according to good research 
practice guidelines and may perform quality assurance audits for protocol compliance. The LI and 
authorized staff from the participating research institutions; the National Institute on Drug Abuse 
Clinical Trials Ne twork (NIDA CTN, the study sponsor); and other agencies such as the 
Department of Health and Human Services (HHS), the Office for Human Research Protection 
(OHRP) , and the Institutional Review Board of record may inspect research records for verification 
of data, compliance with federal guidelines on human participant research, and to assess 
participant safety.  
 Study Documentation  
Each participating University site will maintain appropriate study documentation (including 
research records) for this study , in compliance with ICH E6 and regulatory and institutional 
 NIDA CTN -0093 Version 2.0 
 PharmScreen  May. 25, 21  
 
25 
 requirements for the protection of confidentiality of participants. Study documentation includes 
sponsor -investigator correspondence, signed protocol and amendments, Ethics Review 
Committee or Institutional Review Board correspondence, and approved e- consent document . As 
part of participating in a NIDA -sponsored study, each site will permit authorized representatives 
from NIDA and regulatory agencies to examine (and when permitted by law, to copy)  records for 
the purposes of quality assurance reviews, audits, and evaluation of the study safety, progress, 
and data validity.  
 Protocol Deviations   
Any departure from procedures and requirements outlined in the protocol will be classified as 
either a major or minor protocol deviation. The difference between a major and minor protocol 
deviation has to do with the seriousness of the event and the corrective action required. A minor 
protocol deviation is considered an action (or inaction) that by itself is not likely to affect the 
scientific soundness of the investigation or seriously affect the safety, rights, or welfare of a study 
participant. Major protocol deviations are departures that may compromise the participant safety, participant rights, inclusion/exclusion criteria or the integrity of study data and could be cause for 
corrective actions if not rectified or prevented from re- occurrence. Sites will be responsible for 
developing corrective action plans for both major and minor deviations as appropria te within a 
reasonable period of time following their discovery. Those corrective action plans may be 
reviewed/approved by the Lead Node with overall approval by the IRB  of record. All protocol 
deviations will be monitored at each site for (1) significance, (2) frequency, and (3) impact on the 
study objectives to ensure that site performance does not compromise the integrity of the study .  
All protocol deviations will be recorded in a REDCap form developed for this project.  
 
Additionally, each site is responsible for reviewing the IRB  of record’s definition of a protocol 
deviation or violation and understanding which events need to be reported. Sites must recognize 
that the CTN and IRB definition of a reportable event may differ and act accordingly in following 
all reporting requirements for both entities.  
 Safety Monitoring  
 Data and Safety Monitoring Board (DSMB)   
This study is not an intervention trial and will not require a Data and Safety Monitoring Board. The Lead Investigator along with the Co- Lead Investigator and sub- investigators are 
responsible for adhering to the Data and Safety Monitoring Plan.  
 Training  
The CTN -0093 study staff will be trained as specified in the study Training Plan. Training will 
include Human Subjects Protection (HSP) and Good Clinical Practice (GCP) as well as protocol -
specific training on assessments, study procedures, data management, quality assurance, etc.  
 
 NIDA CTN -0093 Version 2.0 
 PharmScreen  May. 25, 21  
 
26 
 
 DATA MANAGEMENT   
 Design and Development   
The OVN and University of Utah  will be responsible for development of eCRFs, development and 
validation of the study database, ensuring data integrity, and training site and participating 
research  staff on applicable data management procedures. The remainder of this section provides 
an overview of the Data Management Plan associated with this protocol.   
 Site Responsibilities   
The data management responsibilities of each individual site will be specified by the OVN and University of Utah  and outlined in the Data Management Plan.  Given the fact that data in this 
study are entered remotely  by study participants following contact with the pharmacy recruitment 
sites, limited responsibilities  are designated to these sites. However, one important note regarding 
the Data Management Plan is that it will include procedures, for example, regarding how Kroger 
staff will capture: if  patients were informed about the study and how  they were informed about the 
study . The Plan will also discuss, for example, how these data will be shared on a scheduled 
basis  with OVN and the University of Utah for assessing sampling bias.  
 Data Center Responsibilities   
The OVN and University of Utah  will collaborate to 1) develop a Data Management Plan and will 
conduct data management activities in accordance with that plan, 2) provide guidance for  eCRFs 
for the collection of all data required by the study, 3) develop data dictionaries for each eCRF that 
will comprehensively define each data element, 4) conduct ongoing data monitoring activities on 
study data from all participating sites, 5) conduct  any preliminary analysis data cleaning activities 
as needed, and 6) conduct  final study data cleaning.  
 Data Collection   
The data collection process consists of direct data entry at the recruitment pharmacies  and/or by 
participants into the REDCap forms and surveys. Data entry into REDCap  should be completed 
according to the instructions provided and project specific training. Assessments programmed in REDCap will use validation rules, integrity checks, and hard stops as needed to ensure that data 
are as complete and accurate as possible.  For instance,  validity checks will employ skip logic to 
ensure certain item sets are not available to respondents once initial responses are given (e.g., alcohol consumption questions will not be available to those who report they do not drink). Regarding completeness of responses , all survey response sets will require every item to be 
answered in order to complete the survey. However, to preserve participants’ rights to not respond to any item they wish, the response set will include an option that will allow the participant to 
indicate they wish to not respond to the item.  This process will ensure survey data completion 
with minimal missing values.  Furthermore, given that data are entered directly into the REDCap 
survey by participants without requiring interviewing or data transcr iption by research staff, we 
anticipate a high level of validity and accuracy  (absence of data entry errors)  in this project.  
 Data Merge  
Data collected in  the health survey from study participants will be regularly  merged with NS 
metric data from Appriss Health. OVN and University of Utah staff will securely share participant 
contact information, dispensing pharmacy, and demographic information with Appriss who will 
deterministically link NS metric data. Linked data will be returned from Appriss to the OVN  and 
the University of Utah.  
 NIDA CTN -0093 Version 2.0 
 PharmScreen  May. 25, 21  
 
27 
 
 Data Acquisition and Entry  
Completed forms and electronic data will be entered into REDCap  in accordance with the 
instructions provided by the OVN and University of Utah . Only authorized individuals shall have 
access to eCRFs.  
 Data Transfer/Lock  
Data will be transmitted by the OVN and the University of Utah  to the NIDA central data repository 
as requested by NIDA. The OVN and University of Utah  will conduct final data quality assurance 
checks and “lock” the study database from further modification. The final analysis dataset will be 
returned to NIDA, as requested, for storage and archive.  We will comply with the following policy 
regarding the pr eparation and transfer of the study data: 
 
“Data from CTN trials are  posted 18 months after the final database lock or after 
the primary manuscript is published, whichever comes first. All of the data are de-identified, and only raw data (i.e., no analysis  datasets or derived variables) are 
provided. Data documentation, consisting of all annotated case report forms 
(CRFs), the data dictionary, and de- identification notes, is provided to users to 
assist in data interpretation. Protocol documentation, including a brief study description, the study protocol, and a link to the primary manuscript, is also 
provided, and users are encouraged to consult these documents for insight 
regarding proper interpretation of the data .” 
 Data Training  
The Training Plan for res earch  staff includes provisions for training on assessments, eCRF 
completion guidelines, data management procedures, and the use of REDCap.  
 Data Quality Assurance  
To address the issue of data entry quality, the OVN and University of Utah  will follow a Dat a 
Management  Plan. Data quality summaries will be made available during the course of the 
protocol , and acceptable quality level prior to study lock or closeout will be established as a part 
of the Data Management Plan. Data quality will be assessed in regularly scheduled study 
meetings  (not to occur more than weekly and less than monthly) . For these meeting s, a data 
quality summary report will be made available to the research team. By pharmacy site, the report will include information, such as:  
 
 Number of interest forms with missing data  
 Description of missing data on the interest form  
 Number of health assessment surveys with missing data  
 D escription of missing data on health assessment surveys  
 Number of surveys linked to the NS metric  
 Description of surveys/participants with unlinked surveys  
 NIDA CTN -0093 Version 2.0 
 PharmScreen  May. 25, 21  
 
28 
 
 PUBLICATIONS AND OTHER RIGHTS   
Per NIH policy, the results of the proposed study  are to be made available to the research 
community and to the public at large. The planning, preparation, and submission of publicat ions 
will follow the policies of the Publications Committee of the CTN.  
  
 NIDA CTN -0093 Version 2.0 
 PharmScreen  May. 25, 21  
 
29 
 
 PROTOCOL SIGNATURE  PAGE   
SPONSOR’S REPRESENTATIVE (CCTN SCIENTIFIC OFFICER OR DESIGNEE)  
     
          
Printed Name   Signature   Date  
ACKNOWLEDGEMENT BY INVESTIGATOR:  
• I am in receipt of version 2.0 of the protocol and agree to conduct this study in accordance 
with the design and provisions specified therein. 
• I agree to follow the protocol as written except in cases where necessary to protect the 
safety, rights, or welfare of a participant, an alteration is required, and the sponsor and IRB have been notified prior to the action.  
• I will ensure that the requirements relating to obtaining e- consent and institutional review 
board (IRB) review and approval in 45 CFR 46 are met.  
• I agree to personally conduct or supervise this investigation at this site and to ensure that all site staff assisting in  the conduct of this study are adequately and appropriately trained 
to implement this version of the protocol and that they are qualified to meet the responsibilities to which they have been assigned.  
• I agree to comply with all the applicable federal, state, and local regulations regarding the obligations of clinical investigators as required by the Department of Health and Human 
Services (DHHS), the state, and the IRB.  
 
UNIVERSITY SITE’S PRINCIPAL INVESTIGATOR  
          
Printed Name   Signature   Date  
 
University  Name         
Node Affiliation     
 
 
  
 NIDA CTN -0093 Version 2.0 
 PharmScreen  May. 25, 21  
 
30 
 
 REFERENCES   
1. McNeely J, Wu LT, Subramaniam G, et al. Performance of the Tobacco, Alcohol, 
Prescription Medication, and Other Substance Use (TAPS) Tool for Substance Use 
Screening in Primary Care Patients. Annals of internal medicine. 2016;165(10):690- 699. 
2. Humeniuk R , Ali R. Validation of the Alcohol, Smoking and Substance Involvement 
Screening Test (ASSIST) and Pilot Brief Intervention: A Technical Report of Phase II Findings of the WHO ASSIST Project. Geneva: WHO;2006.  
3. Inc. AH. NarxCare User Guide. Louisville, KY : Appriss Health Inc. ;n.d.  
4. Huizenga J, Breneman B, Patel V, Speights D. NARxCHECK® Score as a Predictor of Unintentional Overdose Death. Louisville, KY: Appriss;2016.  
5. Knisely JS, Wunsch MJ, Cropsey KL, Campbell ED. Prescription Opioid Misuse Index: A brief questionnaire to assess misuse. Journal of Substance Abuse Treatment. 
2008;35(4):380 -386. 
6. Keller S, Bann CM, Dodd SL, Schein J, Mendoza TR, Cleeland CS. Validity of the brief 
pain inventory for use in documenting the outcomes of patients with noncancer pain. Clin 
J Pain. 2014;20(5):309 -319. 
7. Luo X, George ML, Kakouras I, et al. Reliability, validity, and responsiveness of the short 
form 12 -item survey (SF -12) in patients with back pain. Spine. 2003;28(15):1739- 1745.  
8. Kroenke K, Spitzer RL, Williams JBW. The Patient Health Questionnaire- 2: Validity of a 
Two-Item Depression Screener. Medical Care. 2003;41(11):1284 -1292.  
9. Fernandez AC, Bush C, Bonar EE, Blow FC, Walton MA, Bohnert ASB. Alcohol and 
Drug Overdose and the Influence of Pain Conditions in an Addiction Treatment Sample. 
Journal of addiction medicine. 2019;13(1):61 -68. 
10. SAMHSA. Key substance use and mental health indicators in the United States: Results 
from the 2017 National Survey on Drug Use and Health (HHS Publication No. SMA 18-5068, NSDUH Series H -53). . Rockville, MD: Substance Abuse and Mental Health 
Services Administration, Center for Behavioral Health Statistics and Quality 2018.  
11. Al-Tayyib AA, Koester S, Riggs P. Prescription opioids prior to injection drug use: 
Comparisons and public health implications. Addictive behaviors. 2017;65:224- 228. 
12. Carlson RG, Nahhas RW, Martins SS, Daniulaityte R. Predictors of transition to heroin use among initially non- opioid dependent illicit pharmaceutical opioid users: A natural 
history study. Drug and alcohol dependence. 2016;160:127 -134. 
13. Cerda M, Santaella J, Marshall BD, Kim JH, Martins SS. Nonmedical Prescription Opioid Use in Childhood and Early Adolescence Predicts Transitions to Heroin Use in Young  
Adulthood: A National Study. The Journal of pediatrics. 2015;167(3):605 -612.e601- 602. 
14. Dasgupta N, Creppage K, Austin A, Ringwalt C, Sanford C, Proescholdbell SK. 
Observed transition from opioid analgesic deaths toward heroin. Drug and alcohol 
dependence. 2014;145:238- 241. 
15. Dertadian GC, Maher L. From oxycodone to heroin: two cases of transitioning opioid use 
in young Australians. Drug and alcohol review. 2014;33(1):102 -104. 
16. Harocopos A, Allen B, Paone D. Circumstances and contexts of heroin init iation 
following non- medical opioid analgesic use in New York City. The International journal 
on drug policy. 2016;28:106- 112. 
17. Lake S, Milloy MJ, Dong H, et al. Initiation into prescription opioid injection and associated trends in heroin use among people who use illicit drugs. Drug and alcohol 
dependence. 2016;169:73- 79. 
18. Mars SG, Bourgois P, Karandinos G, Montero F, Ciccarone D. "Every 'never' I ever said came true": transitions from opioid pills to heroin injecting. The International journal on drug policy. 2014;25(2):257- 266. 
 NIDA CTN -0093 Version 2.0 
 PharmScreen  May. 25, 21  
 
31 
 19. Miech R, Johnston L, O'Malley PM, Keyes KM, Heard K. Prescription Opioids in 
Adolescence and Future Opioid Misuse. Pediatrics. 2015;136(5):e1169 -1177.  
20. Muhuri PK, Gfroerer JC, Davies MC. Associations of Nonmedical Pain Reliever Use and 
Initiation of Heroin Use in the United States. Rockville, MD: SAMHSA, Center for 
Behavioral Health Statistics and Quality;2013.  
21. Palamar JJ, Shearston JA, Dawson EW, Mateu- Gelabert P, Ompad DC. Nonmedical 
opioid use and heroin use in a nationally representative sample of us high school 
seniors. Drug and alcohol dependence. 2016;158:132- 138. 
22. Young AM, Havens JR. Transition from first illicit drug use to first injection drug use among rural Appalachian drug users: a cross -sectional comparison and retrospective 
survival analysis. Addiction (Abingdon, England). 2012;107(3):587 -596. 
23. Scholl L, Puja S, Kariisa M, Wilson N, Baldwin G. Drug and Opioid- Involved Overdose 
Deaths — United States, 2013–2017. Atlanta, GA: CDC;2018.  
24. ChainDru gStores N. 2011- 2012 Chain Pharmacy Industry Profile. Alexandria, VA: 
National Association of Chain Drug Stores;2011. 
25. CDC. Select features of state pharmacist collaborative practice laws. . Atlanta, GA: US 
Department of Health and Human Services, Centers for Disease Control and 
Prevention;2013.  
26. Peacock G, Kidd R, Rahman A. Patient care services in independent community 
pharmacies: A descriptive report. Journal of the American Pharmacists Association. 
2007;47(6):768a -771a.  
27. Riffkin R. Americans Ra te Nurses Highest on Honesty, Ethical Standards. 2014; 
http://www.webcitation.org/6hZbvKPDQ
. Accessed May 17, 2016.  
28. Dhital R, Whittlesea CM, Norman IJ, Milligan P. Community pharmacy service users' 
views and perceptions of alcohol screening and brief intervention. Drug And Alcohol 
Review. 2010;29(6):596- 602. 
29. Cochran G, Field C, Lawson K, Erickson C. Pharmacists' knowledge, attitudes and 
beliefs regarding screening and brief intervention for prescription opioid abuse: a survey of Utah and Texas pharmacists. Journal of Pharmaceutical Health Services Research. 
2013;4(2):71 -79. 
30. Cochran G, Field C, Lawson K. Pharmacists Who Screen and Discuss Opioid Misuse 
With Patients: Future Directions for Research and Practice. J Pharm Pract. 2014.  
31. Cochran G, Bacci JL, Ylioja T, et al. Prescription opioid use: Patient characteristics and misuse in community pharmacy. Journal of the American Pharmacists Association. 
2016;56(3):248 -256.e246.  
32. Cochran G, Rubi nstein J, Bacci JL, Ylioja T, Tarter R. Community Pharmacy and Opioid 
Pain Medication: Screening Patients who Misuse or are At Risk for Misuse. 2015, November.  
33. Cochran G, Rubinstein J, Bacci JL, Ylioja T, Tarter R. Screening community pharmacy patients  for risk of prescription opioid misuse Journal of addiction medicine. 
2015;9(5):411 -416. 
34. Thomas CP, Kim M, Nikitin RV, Kreiner P, Clark TW, Carrow GM. Prescriber response to unsolicited prescription drug monitoring program reports in Massachusetts. 
Pharmacoepidemiology and drug safety. 2014;23(9):950- 957. 
35. Bao Y, Pan Y, Taylor A, et al. Prescription Drug Monitoring Programs Are Associated 
With Sustained Reductions In Opioid Prescribing By Physicians. Health affairs (Project 
Hope). 2016;35(6):1045- 1051.  
36. Dowell D, Zhang K, Noonan RK, Hockenberry JM. Mandatory Provider Review And Pain Clinic Laws Reduce The Amounts Of Opioids Prescribed And Overdose Death Rates. 
Health Aff (Millwood). 2016;35(10):1876 -1883.  
 NIDA CTN -0093 Version 2.0 
 PharmScreen  May. 25, 21  
 
32 
 37. Manasco AT, Griggs C, Leeds R, et al. Characteristics of state prescription drug 
monitoring programs: a state -by-state survey. Pharmacoepidemiology and drug safety. 
2016;25(7):847 -851. 
38. Ali MM, Dowd WN, Classen T, Mutter R, Novak SP. Prescription drug monitoring 
programs, nonmedical use of prescription drugs, and heroin use: Evidence from the 
National Survey of Drug Use and Health. Addict Behav. 2017;69:65 -77. 
39. Kreiner PW, Strickler GK, Undurraga EA, Torres ME, Nikitin RV, Rogers A. Validation of 
prescriber risk indicators obtained from prescription drug monitoring program data. Drug Alcohol Depend. 2017;173 Suppl 1:S31 -s38. 
40. Lin DH, Lucas E, Murimi IB, et al. Physician attitudes and experiences with Maryland's prescription drug monitoring program (PDMP). Addiction. 2017;112(2):311 -319. 
41. Young LD, Kreiner PW, Panas L. Unsolicited Reporting to Prescribers of Opioid Analgesics by a State Prescription Drug Monitoring Program: An Observational Study with Matched Comparison Group. Pain Med. 2017. 
42. Paulozzi LJ, Kilbourne EM, Desai HA. Prescription Drug Monitoring Programs and Death Rates from Drug Overdose. Pain Medicine. 2011;12(5):747- 754. 
43. Patrick SW, Fry CE, Jones TF, Buntin MB. Implementation Of Prescription Drug Monitoring Programs Associated With Reductions In Opioid -Related Death Rates. 
Health Aff (Millwood). 2016;35(7):1324 -1332.  
44. Nam YH, Shea DG, Shi Y, Moran JR. State prescription drug monitoring programs and fatal drug overdoses. Am J Manag Care. 2017;23(5):297 -303. 
45. Cochran G, Bacci JL, Ylioja T, et al. Prescription opioid use: Patient characteristics and misuse in community pharmacy. Journal of the American Pharmacists Association : JAPhA. 2016.  
46. Cochran G, Gordon AJ, Field C, et al. Developing a framework of care for opioid medication misuse in community pharmacy. Research in Social and Administrative 
Pharmacy. 2016;12(2):293- 301. 
47. Cochran G, Field C, Karp J, et al. A community pharmacy intervention for opioid 
medication misuse: A pilot randomized clinical trial. Journal of the American Pharmac ists 
Association : JAPhA. 2018;58(4):395 -403. 
48. Schwartz RP, McNeely J, Wu LT, et al. Identifying substance misuse in primary care: 
TAPS Tool compared to the WHO ASSIST. Journal of substance abuse treatment. 
2017;76:69 -76. 
49. Sullivan MD, Edlund MJ, Fan M- Y, Devries A, Brennan Braden J, Martin BC. Risks for 
possible and probable opioid misuse among recipients of chronic opioid therapy in 
commercial and medicaid insurance plans: The TROUP Study. Pain. 2010;150(2):332 -
339. 
50. White AG, Birnbaum HG, Schiller M, Tang J, Katz NP. Analytic models to identify 
patients at risk for prescription opioid abuse. The American Journal Of Managed Care. 
2009;15(12):897 -906. 
51. Cochran G, Gordon AJ, Lo- Ciganic WH, et al. An Examination of Claims -based 
Predictors of Overdose from a Large Medicaid Program. Med Care. 2017;55(3):291- 298. 
52. Cochran G, Lo- Ciganic WH, Gellad WF, et al. Prescription Opioid Quality Measures 
Applied Among Pennsylvania Medicaid Enrollees. Journal of managed care & specialty pharmacy. 2018;24(9):875- 885. 
53. McNeely J, Strauss SM, Rotrosen J, Ramautar A, Gourevitch MN. Validation of an audio 
computer -assisted self -interview (ACASI) version of the alcohol, smoking and substance 
involvement screening test (ASSIST) in primary care patients. Addiction. 2016;111(2):233 -244. 
54. NIDA_CTN. NIDA CTN Protocol 0059. The TAPS Tool: Screen and Brief Assessment 
Tool Validation  Study. Bethesda, MD: NIDA;2014.  
 NIDA CTN -0093 Version 2.0 
 PharmScreen  May. 25, 21  
 
33 
 55. Han B, Compton WM, Blanco C, Crane E, Lee J, Jones CM. Prescription Opioid Use, 
Misuse, and Use Disorders in U.S. Adults: 2015 National Survey on Drug Use and 
Health. Ann Intern Med. 2017;167(5):293 -301. 
56. Swets JA, Dawes RM, Monahan J. Psychological Science Can Improve Diagnostic Decisions. Psychological Science in the Public Interest. 2000;1(1):1 -26. 
57. Youngstrom EA. A Primer on Receiver Operating Characteristic Analysis and Diagnostic Efficiency Statistics for Pediatric Psychology: We Are Ready to ROC. Journal of 
Pediatric Psychology. 2014;39(2):204 -221. 
58. Obuchowski N. Fundamentals of Clinical Research for Radiologists. American Journal of 
Roentgenology. 2005;184:364- 372. 
59. Cohen J. A Coefficient of Agreement for Nominal Scales. Educational and Psychological 
Measurement. 1960;20(1):37 -46. 
60. Landis JR, Koch GG. The measurement of observer agreement for categorical data. 
Biometrics. 1977;33(1):159- 174. 
61. Rough K, Huybrechts KF, Hernandez -Diaz S, Desai RJ, Patorno E, Bateman BT. Using 
prescription claims to detect aberrant behaviors with opioids: comparison and validation 
of 5 algorithms. Pharmacoepidemiol Drug Saf. 2018. 
62. Compton WM, Cottler LB, Dorsey KB, Spitznagel EL, Mager DE. Comparing 
assessments of DSM -IV substance dependence disorders using CIDI -SAM and SCAN. 
Drug and alcohol dependence. 1996;41(3):179 -187. 
63. Smith TC, Smith B, Jacobson IG, Corbeil TE, Ryan MAK. Reliability of Standard Health 
Assessment Instruments in a Large, Population- Based Cohort Study. Annals of 
Epidemiology. 2007;17(7):525 -532. 
64. Spitzer RL, Kroenke K, Williams JB. Validation and utilit y of a self -report version of 
PRIME -MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. 
Patient Health Questionnaire. JAMA. 1999;282(18):1737 -1744.  
  
 NIDA CTN -0093 Version 2.0 
 PharmScreen  May. 25, 21  
 
34 
 
 APPENDIX: DATA AND SAFETY MONITORING PLAN  
Data and Safety Monitoring Plan  
1.0 BRIEF STUDY OVERVIEW  
Using opioid therapy to treat pain effectively, while minimizing potential adverse consequences, 
is an important goal. Appriss Health has developed the NS metric , which uses PDMP  data on 
opioid and benzodiazepine prescriptions and aberrant drug behavior (e.g., multiple providers, 
pharmacies, etc.) to compute a score quantifying the extent of the patient’s opioid risk in relation 
to all prescription opioid users. The association between the NS metric and other indicators of 
opioid- related risk  has not been evaluated, and hence, the degree to which this metric is a 
useful screening tool is unknown.  
 
The primary objective of this one group, cross -sectional, validation study is to evaluate the 
concurrent validity of the NS metric as a clinical measure of opioid utilization risk  and establish 
clinically useful risk  level thresholds relative to the World Health Organization Alcohol, Smoking, 
and Substance Involvement Screening Test (WHO ASSIST). A secondary objective of the study 
is to collect  validity data on the Tobacco, Alcohol, Prescription medication and other Substances 
(TAPS) tool in a large sample of individuals filling opioid pain medications.  
 
Participant Inclusion Criteria  
Potential participants must : 
1. be dispensed ≥1 opioid medicat ion (including tramadol) by a participating Kroger 
Pharmacy;  
 
2. be ≥18 years of age according to Kroger Pharmacy data and self -report  
 Participant Exclusion Criteria  
Potential participants must not self -report : 
1. not solely filling buprenorphine or buprenorphine combination products i.e., patients receiving OUD treatment with no other opioid medication use; 
 
2. currently receiving treatment for cancer;  
 
3. having previously completed the survey (this will be re -verified by OVN staff by 
examining identifying information following health assessment submission);  
 
4. having current involvement with the criminal justice system that has, or could, lead to 
incarceration  
Sample Size  
This study will recruit  approximately  1,523 participants.  
2.0 STUDY MANAGEMENT  
1. List of participating enrolling clinics or data collection centers: All potential participants will be 
Kroger community pharmacy patients dispensed  opioid medications.  
2. Project timetable: This study will take approximately 24 months to complete. Data collection 
will require 6 -8 months and data analysis will require approximately 3-6 months . 
 NIDA CTN -0093 Version 2.0 
 PharmScreen  May. 25, 21  
 
35 
  
3. Target population distribution: As noted above, based on our previous research, we anticipate 
57% of participants will be women (n=868). In terms of racial distribution, we anticipate the 
population will generally reflect that of the states where participants are recruited.  The 
following estimates assume an even distribution of participant recruitment across study sites. For Ohio, we anticipate 82.2% (n=1002) will be white, 12 .9% (n=157) black or African 
American, 2.3% (n=28) Asian, and 2.3% (n=28) from two or more races. Of these, we anticipate 3.8% (n=46) will be Hispanic or Latino. For Indiana, we anticipate 83.9% (n=256) will be white, 9.3% (n=28)  black or African American,  2.1% Asian (n=6), and 2.3% from two 
or more races (n=7). Of these, we anticipate 6.7% (n=20) will be Hispanic or Latino.  
3.0 DATA MANAGEMENT AND ANALYSIS  
1. Data acquisition and transmission: Information for study  participants  will be obtained from two 
sources.  The first source will be from s elf-reported responses on REDCap forms, including 
contact information, demographics, and health information. The second source will be Appriss 
Health , who will provide the NS metric for all patients enrolled in the study. All research staff 
will be trained in Good Clinical Practice (GCP) guidelines. In addition, demographic information about all patients informed about the study  will be obtained from the participating 
Kroger pharmacies. Only research staff members directly involved with the study will have 
access to identifying information for the participants.  
 
2. Data entry methods: Demographic and clinical data for study participants will be managed in 
REDCap, a software toolset and workflow methodology for collection and mana gement of 
clinical research data developed by Vanderbilt University, in collaboration with institutional partners including the University of Cincinnati Academic Health Center. Only the necessary 
study personnel will have access to the database. 
 
3. A priori statistical  analysis plan: Our a priori analyses to identify clinical cutoff values will 
involve assessing the ability of the NS metric to discriminate between low, moderate, and 
high-risk opioid use from the WHO ASSIST via receiver operating curve charact eristic (ROC) 
analyses. Area under the ROC curve (AUC) values will be used to determine the accuracy of discrimination threshold levels, and we will identify sensitivity and specificity values balancing 
low false positive and low false negative rates to determine the NS metric thresholds that 
classify the specified use thresholds from these opioid measures. Cohen’s Kappa Coefficient s 
59,60  will be used to evaluate agreement  between the identified thresholds and WHO ASSIST 
risk groups.  We will further establish the concurrent validity of the NS metric corresponding to 
the WHO ASSIST using: Spearman’s rho correlation analyses and logistic regression models. 
61-64  Statistical significance values (p<0.05) and magnitudes of correlation and agreement will 
be used to assess association between indicators.  Detailed specifications of study variables 
and a priori  and exploratory  analytical procedures are described in the CTN- 0093 SAP.  
4.0 OVERSIGHT OF CLINICAL RESPONSIBILITIES  
A. Lead Investigator  
The Lead Investigator, with assistance from the Co -Lead Inves tigator and investigative team,  is 
responsible for study oversight, including ensuring human research subject protection. This study 
will not use any  clinical interventions and t here are no expec ted adverse events  during the single 
on-line completion of the surveys. The only expected risk to participants is a loss of confidentiality, 
which will be minimized by utilizing an encrypted REDCap platform. Any breach of confidentiality will be reported on a protocol deviation form.   
 NIDA CTN -0093 Version 2.0 
 PharmScreen  May. 25, 21  
 
36 
 B. Data and Safety Monitoring Board (DSMB)  
This study  is not an intervention trial and will not require  a Data  and Safety  Monitoring Board.  
The Lead  Investi gator  along with the Co-Lead Investigator  and sub-investigators  are 
responsible for adhering  to the Data  and Safety  Monitoring  Plan. 
C. Quality Assurance (QA) Monitoring  
Study  monitoring will be conducted on a regular basis using local QA monitor s. QA monitor s will 
assess compliance with the protocol,  GCP requirements , and other applicable regulatory 
requirements, as well as  document the integrity of the study  progress. Areas of particular concern 
will be protocol adherence, IRB reviews and approvals,  and regulatory documents. The monitors 
will interact with the participating University site staff to identify issues and re -train the site as 
needed to enhance research quality.  QA Reports will be prepared by the monitors following each 
site visit.  These reports will be sent to the investigative team  and NIDA CCTN. The investig ative 
site will provide direct access to all study related sites (e.g., research office), source 
data/documentation, and reports for the purpose of monitoring and auditing by local Node 
monitors, as well as inspection by local and regulatory authorities.  See protocol sections 10. 4, 
10.10, 10.11,  and 10.13.  
D. Management of Risks to Participants  
Confidentiality  
Confidentiality of participant records will be ensured by encryption and secure storage of any documents that have participant identifiers as well as secure computing procedures for entering 
and transferring electronic data. No identifying information will be disclosed in reports, 
publications , or presentations.  
Information That Meet s Reporting Requirements 
The e-consent document will specify the types of information that are required for reporting and 
that the information will be reported as required. These include suspected or known sexual or 
physical abuse of a child or elders, or threatened violence to self and/or others.  
Pregnancy  
As there is no medication intervention, pregnancy will not be excluded within the context of this 
study.  
5.0 STUDY SAFETY  
Risks:  
Breach of confidentiality: As with any study, there is a potential risk of loss of confidentiality. To 
maintain participant confidentiality, study records and data will be stored in compliance with the 
International Conference on Harmonization (ICH) guidelines. Participant -reported data will be 
collected through REDCap, which is HIPAA -compliant and 21 CFR Part 11- ready for audit trails 
for tracking data manipulation and exports. Emails or text messages between researchers and participants, used in recruitment  efforts, will be dele ted after information exchange. We will train 
all study -related personnel to follow HIPAA regulations for research to ensure confidentiality of all 
data and that the rights of the patients are protected. All data will reside on password- protected 
encrypted computers, with only the investigators and key members of the research team having 
access. A variety of other measures will be taken to protect confidentiality, including: We will 1) 
 NIDA CTN -0093 Version 2.0 
 PharmScreen  May. 25, 21  
 
37 
 assign a unique ID number to each patient, instead of patient names  and 2) restrict access to the 
key linking names and ID numbers to key staff and the PI at each site. Participants will be told 
that agents of the IRB and QA monitors will be allowed to inspect research records related to this 
study, if requested.  
Emotional Di scomfort : The participants may experience some emotional discomfort from 
answering sensitive and/or personal questions. There is the possibility that the participant will feel 
bored. The patient’s ability to respond to study assessments in the privacy of his/her own home 
should help in reducing potential emotional discomfort.  
Benefits :  
Participants may not experience a benefit from participating in this study. Potential benefits include the chance to contribute to a scientific investigation which may benefit other patients like 
themselves in the future. The risk/benefit ratio is favorable and conduct of the research well 
justified.  
6.0 REGULATORY ISSUES 
Reporting of safety concerns to the IRB ad NIDA: The only expected risk to participants is a loss 
of confide ntiality, which will be minimized by utilizing an encrypted REDCap platform. All breaches 
of confidentiality  will be reported to and reviewed by study leadership in regularly scheduled 
meetings (not to occur more than weekly and less than monthly).  
Report ing of IRB action to NIDA : All communications with and actions of the IRB will be kept in a 
regulatory binder specific for this study. Any protocol changes, amendments, or deviations will be submitted to the IRBs and NIDA and the IRB’s actions will then be reported to NIDA. Any other 
IRB actions will be submitted to NIDA.  
Report of changes or amendments to the protocol: All changes and amendments to the protocol 
will be submitted to the IRBs and NIDA. Only after IRB and NIDA approvals are granted will the 
changes and amendments be implemented.  
Stopping rules: Individual study participants will be informed of their right to discontinue study 
participation at any time during the study. The PI may discontinue a participant from the study  if 
deemed clinically appropriate. NIDA has the right to discontinue the investigation at any time.            
Disclosure of conflict of interest : The investigators have no conflicts of interest.  
7.0 DATA MANAGEMENT PROCEDURES  
This protocol will utilize a cent ralized REDCap data capture program. This electronic data capture 
system ( REDCap ) will be developed in collaboration by OVN an and University of Utah teams to 
ensure that guidelines and regulations surrounding the use of computerized systems in clinical studies  are upheld.  Assessments programmed in REDCap will use validation rules, integrity 
checks, and hard stops as needed to ensure that data are as complete and accurate as possible.  
See Protocol section 11.4 for additional details .  
8.0 DATA AND STATISTICS RESPONSIBILITIES OF THE OVN and UNIVERSITY OF 
UTAH  
The OVN and the University Utah  will: 1) develop and apply data management procedures to 
ensure the collection of accurate and good -quality data, 2) eCRFs for the collection of all data 
 NIDA CTN -0093 Version 2.0 
 PharmScreen  May. 25, 21  
 
38 
 required by the study, 3) develop data dictionaries for each eCRF that will comprehensively define 
each data element, 4) prepare instructions for the use of REDCap  and for the completion of 
eCRFs, 5) conduct ongoing monitoring activities on study data collected from all participating sites, and 6) perform data cleaning activities prior to the final study database lock.  
9.0 DATA COLLECTION AND ENTRY  
Data will be entered by pharmacy staff and participants into eCRFs through REDCap . Data will 
be entered into REDCap  in accordance with the instructions provided during protocol -specific 
training and guidelines established by the OVN and the University of Utah . Data entry into the 
eCRFs is performed by authorized individuals . Mentioned above, a ssessments programme d in 
REDCap will use validation rules, integrity checks, and hard stops as needed to ensure that data are as complete and accurate as possible.  The investigator at the participating University  site is 
responsible for maintaining accurate, complete and up-to- date research records. See Protocol 
sections 10.4 and  11.9 that provides overview s of Data Quality Assurance  and Quality Assurance 
Monitoring. 
10.0 DATA MONITORING, CLEANING, AND EDITING 
eCRFs will be monitored for completeness and accuracy throughout the study. Dynamic reports 
listing missing values and forms are available in  REDCap . These reports will be monitored 
regularly by the OVN and the University of Utah . See Protocol section 11.9 that provides an 
overview of Data Quality Assurance. 
Study  progress and data status reports, which provide information on recruitment, availability  of 
primary outcome , regulatory status, and data quality, will be generated regularly  and shared with 
project research leadership and staff . 
11.0 DATABASE LOCK AND TRANSFER  
At the conclusion of data collection for the study, the OVN and University of Utah will perform final 
data cleaning activities and will “lock” the study database from further modification. The final 
analysis dataset will be transferred to the Lead Investi gator or designee. De- identified versions of 
these datasets will also be provided to the NIDA CCTN -designated parties for posting on 
Datashare, as well as storage and archiving. We will comply with the following policy regarding the preparation and transfer of the study data:  
“Data from CTN trials are  posted 18 months after the final database lock or after 
the primary manuscript is published, whichever comes first. All of the data are de-
identified, and only raw data (i.e., no analysis datasets or derived variables) are provided. Data documentation, consisting of all annotated case report forms 
(CRFs), the data dictionary, and de- identification notes, is provided to users to 
assist in data interpretation. Protocol documentation, including a brief study desc ription, the study protocol, and a link to the primary manuscript, is also 
provided, and users are encouraged to consult these documents for insight 
regarding proper interpretation of the data.”  
  
 NIDA CTN -0093 Version 2.0 
 PharmScreen  May. 25, 21  
 
39 
 DSM PLAN ADMINISTRATION 
Responsibility for data and safety monitoring:  the study Lead Investigators will be responsible for 
the safety monitoring of the study participants.  
Frequency of DSM reviews:  The study protocol will be reviewed by the CCTN Protocol review  
Board before recruitment starts. Breaches of confidentiality  will be reviewed by study leadership 
in regularly scheduled meetings for the duration of the study. DSM  reports will be  submitted to 
the IRBs and NIDA  annually .  
Content of DSM report: The DSM report will include a brief description of the study  and any 
changes made. Additionally, we will report baseline sociodemographic characteristics, including 
age, gender, and race of the subjects screened and randomized.  We will also report retention 
rates and the disposition for all study participants. A ny quality assurance issues, regulatory 
issues, and breaches of confidentiality  will be included in the report.  
 